The United States Patent and Trademark Office (US PTO) has recently issued five patents to BIND Biosciences. These patents cover BIND-014, the company’s lead Accurin product candidate for solid cancer tumours, and its Medicinal Nanoengineering platform which enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites.

The newly-issued patents include: US Patent 8,246,968 and US Patent 8,236,330: Both of these patents relate to BIND-014 and its targeting ligand; US 8,206,747 relates to the polymer composition of BIND-014 and US Patent 8,211,473 relates to a lyophilized composition of BIND-014. Both of these patents cover BIND-014 and BIND’s Medicinal Nanoengineering platform; US Patent 8,193,334 relates to BIND’s Medicinal Nanoengineering platform.

“The issuance of these five patents acknowledges the innovative nature of our platform and products, as well as the proprietary methods we use to produce them. We expect additional patent issuances over the coming months continuing to further bolster this broad and growing patent estate,” said Scott Minick, CEO of BIND. “We are highly encouraged by the real world impact of our innovative technology embodied in BIND-014, our lead Accurin product candidate which is showing promising clinical results for solid tumours.”

BIND Biosciences is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins.